Cipla launches therapy for Knee Osteoarthritis ‘Ciplostem’

04 Dec 2025 Evaluate

Cipla has partnered with Stempeutics Research to launch Ciplostem, a therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine. 

Through this launch, Cipla and Stempeutics reaffirm their collective focus on science- driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients’ everyday lives.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1522.10 0.90 (0.06%)
05-Dec-2025 12:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1809.00
Dr. Reddys Lab 1280.00
Cipla 1522.10
Zydus Lifesciences 932.20
Lupin 2100.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×